Thank you JL
I have always valued your posts even if I, on occasion , have disagreed with them .
I know you are an MD .
I am a patient ...diagnosed , hetero FH , CAD , hyperlipidemia and pre diabetic ...so I tend to pay attention to the views of other MD's or those with knowledge in the field.
My primary concern regarding your posts is that those with LDL cholesterol above 180 ...ie likely to be hetero FH , will not seek medical attention or take Statin drugs to lower their LDL ....because MD's such as yourself warn of possible cognitive effects.
In others words ...they will die of a heart attack or stroke ...long before they need to worry about memory loss.
Statin effects on cognition is a murky pool. Your point about the 2013 study, all 5,287 patients , all three years, needs to understand somebody paid for that study and face it, it was most likely a statin company. Cognitive decline is so hard to measure, because the starting off varies so much from person to person. Kasparoff could probably beat both of us in our best chess game even if his cognition was off by 80%.
The fact is cholesterol is found in high concentration in the myelin sheaths that protect nerve transmissions and is a vital structural component of cell membranes. A small study run by a dedicated scientist might hold more truth than a large study influenced by financial considerations. This is not "biostatistics", this reality.
": ) JL
Sentiment: Strong Buy
AMRN Bought pretty full for Earnings, tomorrow- AH
Undervalued, low PPS and just pulled back on solid news. A beat will reignite the momo.
Mar 3 AMRN to announce Q4 earnings After Market (Confirmed)
Mar 3 AMRN Earnings Conference Call at 4:30 PM Listen
China is catching up fast with western in managing medicines (though still a distance to go). CFDA stands for Chinese FDA (no kidding).
Eddingpharma is a relative new company based in Chinese Las Vegas. Now rich Chinese are finding ways to make money. Bet on pharmaceuticals is a very perspective way. There has limited info about Eddingpharma. If they have no problem in raising funds, then they can do a Chinese "Reduce-It" catching up with that in US (slow due to funding) -- say, two years in clinical, one year analyzing and filing and then one year for CFDA review. I believe that Chinese Reduce-It will start later 2015 and the marketing could begin in 2020. Eddinpharma will try very hard to do it for reserving 10 year patent protection. After that, Vascepa will become the largest drug in history (beyond statins).
Because Vascepa if proved to reduce CVD risk could potentially be sold to hundreds millions patients/have hundreds billions USD revenue globally?
JL ..always appreciate your posts ...BUT ...being the Harvard / MIT educated MD you are , is it to much to expected a balanced post from you ?
You cite a very small trial using 128 patients ...if you don't understand the limitations of such a small trial may I suggest a course in bio statistic's to further your knowledge base..
To balance the perspective of that trial you might also have reported on the results of a much larger trial reported in Medscape under " Statins and cognitive decline in older adults etc ) 2013
This trial covered 5,287 patients over an average of 3 yrs
Results " Elderly adults with normal cognition at baseline , using statins , had a slower rate of decline "
I am not advocating Statin use for everyone , however I am concerned that many at high risk of a CV event will avoid using Statins to lower their risk, based on one sided, poorly informed opinions such as yours
What is the reference for this study? My Dad has been having some Cog issues and has been on statins for a while.
I have always been in this stock for the science and as you mention, there is overwhelming credibility in the literature as to the deadly combination of inflammation & Trigs. But....a companies success is not always tied to the quality of their science, but rather the execution of their business plan by management. Additionally, in the case of drug development, you have the added problems introduced by Govt. agencies such as the FDA. The science is not in question, at least in my mind, it is the poor execution of Amarin's management and the bordering on absurd actions of the FDA.
I'm totally with you in spirit but it remains to be seen if the previous wreckage can be overcome. That said, I did just buy another 2000 shares, which I SWORE I would not do. I think that the path is up, but when it comes to this stock I have exceptionally poor prognostication abilities....